life sciences private‑equity fundraising has slipped back from the heights reached during the COVID‑19 surge, according to a recent PEI analysis. The data reveal a decline in capital commitments and deal flow across biotech‑focused funds, signaling a cooling of the boom that once dominated the sector.

During the pandemic, investors poured money into companies developing diagnostics, treatments and vaccines, driving record valuations. As the crisis subsided, enthusiasm waned and the influx of new funds slowed, leaving some firms scrambling to secure follow‑on capital in a tighter market environment.

The downturn affects deal values, with exits now offering lower multiples and valuations that reflect cautious risk appetites. Fund managers face pressure to demonstrate operational efficiency, while limited capital inflows push them to target higher‑growth or niche sub‑sectors within life sciences. Additionally, secondary market activity has increased as institutional investors rebalance portfolios, creating opportunities for smaller funds to capture value from mid‑stage companies.

For investors, the current trend signals a shift toward more selective, evidence‑driven investments in life sciences, underscoring the need for rigorous due diligence before allocating capital. The sector’s future will hinge on sustained innovation rather than pandemic‑era hype.